September 2007
Eli Lilly Seeks European Approval of Alimta®
Eli Lilly is filing for European approval of its Alimta® Injection drug as an initial treatment for non-small cell lung cancer.
Eli Lilly & Co. Data Affirm Benefits of Using Alimta®
Eli Lily says that data from two large, open- label studies show patients experienced one-year survival rates above fifty percent when treated with Alimta®.



